Lantus Solostar Pens 5 x 3 ml -100u/ml (10 pens)
PACKAGE: Lantus Solostar Pens 5 x 3 ml -100u/ml (10 pens)
Buy Lantus Solostar Pen, Lantus Solostar pen is a long-acting insulin, human analog with an active substance insulin glargine (1 ml – 100 units of insulin) and metacresol
Buy Lantus Solostar Pen, Lantus Solostar Pen for sale
Buy Lantus Solostar Pen, Lantus Solostar pen is a long-acting insulin, human analog with an active substance insulin glargine (1 ml – 100 units of insulin) and metacresol (m-cresol) – 2.7 mg, zinc chloride – 0.0626 mg (corresponds to 30 μg zinc), glycerol (85%) – 20 mg, sodium hydroxide – up to pH 4.0, hydrochloric acid – up to pH 4.0, water d/i – up to 1 ml as excipients for blood sugar control.
The remedy is an injectable transparent, colorless, or almost colorless solution. Lantus Solostar insulin pen is prescribed in case of diabetes mellitus requiring insulin treatment in adults, adolescents, and children over 2 years of age.
Dosage and Rules of Administration, Buy Lantus Solostar Pen
Lantus SoloStar should be administered subcutaneously 1 time/day at any time of the day, but every day at the same time. In patients with type 2 diabetes mellitus, the Lantus SoloStar pen can be used both as monotherapy and in combination with other hypoglycemic drugs. Target values for blood sugar levels, as well as the dose and timing of administration or administration of hypoglycemic drugs, should be determined and adjusted individually.
A dose adjustment may also be required, for example, when weight gain occurs, lifestyle changes, the time of administration of the insulin dose is changed, or in other conditions that may increase the predisposition to the development of hypo- or hyperglycemia. Any changes in insulin dose should be done with caution and under medical supervision.
The Lantus SoloStar pen is administered as a subcutaneous injection. Lantus insulin glargine injection of 100 units/ml is not intended for intravenous administration. The long duration of action of insulin glargine as observed only when it is injected into the subcutaneous fat. Intravenous administration of the usual subcutaneous dose can cause severe hypoglycemia. Lantus SoloStar should be injected into the subcutaneous fatty tissue of the abdomen, shoulders, or thighs. The injection sites should be alternated with each new injection within the recommended areas for subcutaneous administration of the drug.
To prevent infection, a pre-filled pen should be used by one patient only and should not be passed on to another person. Do not take Lantus injections with the same pen twice even if the needle has been changed.
Common Side Effects
From the side of metabolism: very common side effect – low blood sugar. Hypoglycemia, the most common adverse reaction to insulin therapy, can occur if the dose of insulin is too high compared to the need for it.
From the immune system: rarely – allergic reactions. Allergic reactions of an immediate type to insulin are rare. Similar reactions to insulin (including insulin glargine) or excipients can be manifested by developing generalized skin reactions, angioedema, bronchospasm, lowering blood pressure, or shock and can thus become life-threatening.
From the nervous system: very rarely – dysgeusia.
From the side of the organ of vision: rarely – visual impairment; retinopathy.
Skin and subcutaneous tissue disorders: often – lipodystrophy (in 1-2% of patients). As with treatment with any other insulin preparations, lipodystrophy and/or localized cutaneous amyloidosis may develop at the site of injection, slowing down the local absorption of insulin. Infrequently – lipoatrophy.
From the musculoskeletal system: very rarely – myalgia.
General disorders and injection site reactions: often – possible side effects include reactions at the site of injection (3-4%) (redness, pain, itching, urticaria, or inflammation); rarely sodium retention, edema.
Important safety information for Lantus: if you notice any long-lasting or serious side effects, apply to your doctor to get medical help right away.
There are no reviews yet.